Severe asthma in the US population and eligibility for mAb therapy

Ayobami Akenroye, Meredith McCormack, Corinne Keet

Research output: Contribution to journalArticle

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology
DOIs
StateAccepted/In press - Jan 1 2020

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Severe asthma in the US population and eligibility for mAb therapy. / Akenroye, Ayobami; McCormack, Meredith; Keet, Corinne.

In: Journal of Allergy and Clinical Immunology, 01.01.2020.

Research output: Contribution to journalArticle

@article{4e0e5716346745ab957b42982a12f8fe,
title = "Severe asthma in the US population and eligibility for mAb therapy",
author = "Ayobami Akenroye and Meredith McCormack and Corinne Keet",
year = "2020",
month = "1",
day = "1",
doi = "10.1016/j.jaci.2019.12.009",
language = "English (US)",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Severe asthma in the US population and eligibility for mAb therapy

AU - Akenroye, Ayobami

AU - McCormack, Meredith

AU - Keet, Corinne

PY - 2020/1/1

Y1 - 2020/1/1

UR - http://www.scopus.com/inward/record.url?scp=85077924817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077924817&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2019.12.009

DO - 10.1016/j.jaci.2019.12.009

M3 - Article

C2 - 31866437

AN - SCOPUS:85077924817

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

ER -